Please ensure Javascript is enabled for purposes of website accessibility

3 Top Stocks to Buy in January

By Keith Speights - Jan 5, 2020 at 9:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're looking for growth, these stocks should deliver.

January ranks as the No. 1 month to buy stocks. But it's in a 12-way tie for first place with all of the other months.

My point, of course, is that anytime is a great time to invest. Starting off the year by choosing stocks with tremendous long-term growth prospects does feel a little extra special, though. And there are plenty of great stocks to consider. Here are three growth stocks that I think are top picks to buy in January (listed in alphabetical order). 

Magnifying glass on top of hundred dollar bills with stock data and a keyboard in the background

Image source: Getty Images.

1. MongoDB

Mongo -- short for humongous -- is a pretty good way to sum up the potential for MongoDB (MDB 6.68%). The global database market is growing rapidly -- IDC projects over 50% growth in just the next four years. Companies increasingly want to store data in the cloud. And much of that data is unstructured, like images and videos. That's the perfect storm for MongoDB.

The company developed a database designed to support unstructured data, as well as structured data, that can be run on-premises or in the cloud. MongoDB uses a "freemium" model where customers can use a limited version of its product for free then migrate to the commercial version to get more features and support. This model has worked really well for the company: MongoDB's revenue has skyrocketed more than fivefold over the last three years.

Sure, MongoDB has plenty of competition. Big database companies with deep pockets such as Oracle don't want to give up their share of the market. However, MongoDB is growing much faster than its well-heeled rivals, in part because its technology was specifically built from the ground up for the database world of today while their technology wasn't.

There are several catalysts that should drive MongoDB stock higher in 2020. The most important is the company's Atlas database-as-a-service product. Revenue from Atlas soared 185% year over in MongoDB's fiscal third quarter and should continue to enjoy great momentum. 

2. The Trade Desk

The Trade Desk (TTD 5.71%) ranks as a leader in a revolution that many investors haven't even heard about. This revolution is the shift from a cumbersome manual process for buying ads to a programmatic advertising model where software is used to buy ads. The Trade Desk's platform has won multiple awards as the best technology available for buying digital ads programmatically.

Most of ad buying and selling still isn't done programmatically, though. That gives The Trade Desk a lot of room to run, especially considering that programmatic advertising is growing five times faster than the overall ad market.  

The explosion in connected television (CTV) is also dramatically expanding the number of available digital ad opportunities. Streaming services such as Hulu that use ad-supported models have increased the appeal for The Trade Desk's technology. And with the potential for other streaming services to offer ad-supported models to reduce costs for consumers, CTV will likely fuel The Trade Desk's growth even more in the future.

Needham picked The Trade Desk as its top stock to buy for 2020. Analyst Laura Martin likes the same growth drivers that I like. She also highlighted the opportunity for the company to benefit from the U.S. election cycle, with an estimated $10 billion in political ad spending projected this year.

3. Vertex Pharmaceuticals

It's no exaggeration to state that Vertex Pharmaceuticals (VRTX 1.23%) has single-handedly changed the dynamics for treating cystic fibrosis (CF). There are only four drugs approved in the U.S. that address the underlying genetic cause of CF. Vertex markets all of them.

This CF franchise has enabled Vertex to grow rapidly over the last several years, but the biotech's growth story isn't over by any means. Vertex's latest CF drug, Trikafta, won U.S. approval in October 2019. Assuming it also obtains approval in Europe, which seems like a good bet, the drug could expand Vertex's addressable patient population by more than 50%.

Vertex's sales will almost certainly soar thanks to Trikafta and to securing key reimbursement deals across the world for its other CF drugs. The company also has its targets set on other rare diseases. Vertex and partner CRISPR Therapeutics, for example, are evaluating a gene-editing therapy for treating rare blood diseases beta-thalassemia and sickle cell disease in early stage clinical studies. In addition to this rare-disease focus, Vertex's pipeline includes promising drugs for alleviating pain. 

My view is that Vertex remains the best biotech stock on the market overall. It claims a monopoly in CF that isn't likely to be challenged anytime soon. It's highly profitable with a growing cash stockpile. It has a newly approved drug that will greatly expand its market opportunity. And it has a pipeline that holds the potential to give Vertex blockbuster drugs in additional indications beyond CF. All of this makes Vertex a great stock to buy in January along with MongoDB and The Trade Desk.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$255.45 (1.23%) $3.10
The Trade Desk Stock Quote
The Trade Desk
$53.68 (5.71%) $2.90
MongoDB Stock Quote
$245.33 (6.68%) $15.36
Oracle Corporation Stock Quote
Oracle Corporation
$67.04 (-1.85%) $-1.26
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$56.49 (3.16%) $1.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.